Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
Aiko Ogasawara, Taro Hihara, Daisuke Shintani, Akira Yabuno, Yuji Ikeda, Kenji Tai, Keiichi Fujiwara, Keisuke Watanabe, Kosei Hasegawa
Cancer Res Treat. 2020;52(4):1219-1228. Published online 2020 May 6 DOI: https://doi.org/10.4143/crt.2019.688
Citations to this article as recorded by 
DNA methylation marker to estimate ovarian cancer cell fraction
Takahiro Ebata, Satoshi Yamashita, Hideyuki Takeshima, Hiroshi Yoshida, Yoshiko Kawata, Nao Kino, Toshiharu Yasugi, Yasuhisa Terao, Kan Yonemori, Tomoyasu Kato, Toshikazu Ushijima
Medical Oncology.2022;[Epub] CrossRef
Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients
Dimitra Stergiopoulou, Athina Markou, Lydia Giannopoulou, Paul Buderath, Ioanna Balgkouranidou, Nikolaos Xenidis, Stylianos Kakolyris, Sabine Kasimir-Bauer, Evi Lianidou
Cancers.2022; 14(15): 3790. CrossRef
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
Christen A. Khella, Gaurav A. Mehta, Rushabh N. Mehta, Michael L. Gatza
Journal of Personalized Medicine.2021; 11(2): 149. CrossRef
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer
Daisuke Shintani, Taro Hihara, Aiko Ogasawara, Sho Sato, Akira Yabuno, Kenji Tai, Keiichi Fujiwara, Keisuke Watanabe, Kosei Hasegawa
International Journal of Gynecologic Cancer.2020; 30(9): 1340. CrossRef